Literature DB >> 8302756

Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

J J Bergers1, W Den Otter, H F Dullens, C T Kerkvliet, D J Crommelin.   

Abstract

Interleukin-2 (IL-2) incorporation in liposomes was studied under different conditions. Information was obtained on the mechanism of interaction of glycosylated recombinant IL-2 with liposomal bilayers. This information was utilized to formulate liposomes with high levels of incorporated IL-2. Multilamellar vesicles were prepared by hydration of a lipid film with an IL-2 solution. The incorporation efficiency, measured with a bioassay after forced release of IL-2 from the vesicles, was strongly dependent on the charge of the liposomes and the pH and ionic strength of the hydration medium. Negatively charged liposomes composed of phosphatidylcholine/phosphatidylglycerol (9:1) and prepared with IL-2 dissolved in 10 mM NaAc/270 mM glycerol, 0.1% BSA, pH 5, showed the highest incorporation efficiency (81%) among the investigated preparations. This type of liposome was selected for further study. Electrostatics play a crucial role in the process of IL-2 association with this type of liposome. Initial studies concerning induction of protective tumor immunity by immunization with reconstituted membranes with muramyl tripeptide phosphatidylethanolamine indicate that coinjection of IL-2-containing liposomes provided a significant enhancement of the immune response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8302756     DOI: 10.1023/a:1018913912580

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes.

Authors:  I N Mbawuike; P R Wyde; P M Anderson
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

Review 2.  Human recombinant interleukin-2 as an experimental therapeutic.

Authors:  J L Winkelhake; S S Gauny
Journal:  Pharmacol Rev       Date:  1990-03       Impact factor: 25.468

3.  Pharmacokinetics of recombinant interleukin 2 in humans.

Authors:  M W Konrad; G Hemstreet; E M Hersh; P W Mansell; R Mertelsmann; J E Kolitz; E C Bradley
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

4.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

5.  Enhancement of interleukin-2 activity by liposomes.

Authors:  M L Joffret; S Morgeaux; C Laclerc; D Oth; C Zanetti; P Sureau; P Perrin
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

6.  Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles.

Authors:  L D Mayer; M J Hope; P R Cullis; A S Janoff
Journal:  Biochim Biophys Acta       Date:  1985-07-11

Review 7.  Interleukin 2: a class of T cell growth factors.

Authors:  J Watson; D Mochizuki
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

8.  Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs.

Authors:  R J Ho; R L Burke; T C Merigan
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.

Authors:  J J Bergers; W Den Otter; J W De Groot; A W De Blois; H F Dullens; P A Steerenberg; D J Crommelin
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Antitumor effect of IL-2 liposome.

Authors:  H Konno; A Yamashita; T Tadakuma; S Sakaguchi
Journal:  Biotherapy       Date:  1991
View more
  2 in total

1.  Emerging Role for Use of Liposomes in the Biopreservation of Red Blood Cells.

Authors:  Jelena L Holovati; Jason P Acker
Journal:  Transfus Med Hemother       Date:  2011-03-21       Impact factor: 3.747

Review 2.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.